Therefore, miR-7 acted as a bridge between NAFLD and coronary diseases by targeting the LAMP1/Cathepsin B/NLRP3 signaling pathway. The gene discussed is CTSB; the disease is metabolic dysfunction-associated steatotic liver disease.